IL-6 is a cytokine that plays an important role in cancer progression [44], and treatments that inhibit IL-6 signalling are expected to have a beneficial effect in lymphoid malignancies, as well as in patients with solid tumours, including PCa. The gene discussed is IL6; the disease is cancer.